Review Article Open-Access



Bioactive Compounds in Health and Disease – Focus on Rutin

Marcello Iriti, *, Elena Maria Varoni, *, Sara Vitalini

Department of Biomedical, Surgical and Dental Sciences, Università degli Studi di Milano, Italy

*Corresponding Author: Marcello Iriti, Department of Biomedical, Surgical and Dental Sciences, Università degli Studi di Milano, Italy

§Co-first author: Elena Maria Varoni, Department of Biomedical, Surgical and Dental Sciences, Università degli Studi di Milano, Italy

Submission Date: July 12th, 2023; Acceptance Date: October 5th, 2023; Publication Date: October 10, 2023

Please cite this article as: Iriti M., Varoni E. M., Vitalini S. Bioactive Compounds in Health and Disease – Focus on Rutin. Bioactive Compounds in Health and Disease 2023; 6(10): 235-242. DOI: https://www.doi.org/10.31989/bchd.v6i10.1145

ABSTRACT

The flavonoid rutin was first isolated from rue (*Ruta graveolens* L.) and is used therapeutically as a capillary stabilizing and vasoprotective agent to reduce capillary fragility, although no health claims have been approved in the EU. This article briefly focuses on physicochemical properties, occurrence in foods and oral bioavailability of rutin, with emphasis on human studies. According to the available information, rutin can be considered a promising bioactive compound, despite the paucity of clinical trials. In addition to its therapeutic relevance in pathological and pathophysiological conditions, dietary rutin can also contribute to improve the physiological status of the organism in healthy subjects, thus preventing the onset of non-communicable chronic degenerative diseases.

Keywords: Flavonoids; polyphenols; phenylpropanoids; bioactive phytochemicals; biological activity; oral bioavailability pharmacokinetics; safety; rutin

©FFC 2023. This is an Open Access article distributed under the terms of the Creative Commons Attribution 4.0 License (http://creativecommons.org/licenses/by/4.0)

INTRODUCTION: Rutin (quercetin 3-*O*-rutinoside) is a flavonoid arising from the phenylpropanoid pathway and found in many plant species. It is a rutinoside, a flavonol glycoside derived from quercetin after substitution of the hydroxy group at the C3-position with rutinose, a disaccharide consisting of glucose and a rhamnose molecule (see Graphical abstract). The chemical-physical

properties, toxicity, and occurrence of rutin in selected plant foods are reported in Tables 1-3, respectively. Particularly, high levels of rutin were measured in capers (*Capparis spinosa* L., 332.29 mg/100g FW), olives (*Olea europea* L., 45.36 mg/100 g FW), buckwheat (*Fagopyrum esculentum* Möench, 36.14 mg/100 g FW) and asparagus (*Asparagus officinalis* L., 23.20 mg/100 g FW).

Table 1. Chemical and physical properties of rutin*

| Property | Value |
|---------------------------------|-----------------------------|
| Appearance/physical description | Pale yellow to amber powder |
| Average molecular weight | 610.5175 Da |
| Monoisotopic mass/exact mass | 610.153384912 Da |
| Melting point | 125°C |
| Water solubility | 0.125 mg/mL |
| LogP(o/x) | -2.020 (est) |

*Source: https://pubchem.ncbi.nlm.nih.gov/; h

Table 2. Acute toxicity of rutin*

| Animal model | Route | LD50 |
|--------------|-----------------|-----------|
| Mouse | Intraperitoneal | 200 mg/kg |
| Mouse | Intravenous | 950 mg/kg |
| Rat | Intraperitoneal | 2 g/kg |
| Guinea pig | Intraperitoneal | 2 g/kg |

^{*}Adapted from: https://pubchem.ncbi.nlm.nih.gov/

Table 3. Occurrence of rutin in selected plant foods*

| Foods | | Mean content | | |
|-----------------------------|--------------------------------------|---------------------------------|--|--|
| Cereals and cereal products | | | | |
| Cereals | Buckwheat, groats, thermally treated | 8.96 mg/100 g FW (fresh weight) | | |
| | Buckwheat, refined flour | 5.86 mg/100 g FW | | |
| | Buckwheat, whole grain flour | 36.14 mg/100 g FW | | |
| Vegetables | | | | |
| Fruit vegetables | Olive (black), raw | 45.36 mg/100 g FW | | |
| | Tomato (cherry), whole, raw | 3.33 mg/100 g FW | | |
| | Tomato, whole, raw | 0.14 mg/100 g FW | | |
| Onion-family vegetables | Onion (red), raw | 0.21 mg/100 g FW | | |
| | Onion (yellow), raw | 0.68 mg/100 g FW | | |
| Pod vegetables | Green bean, raw | 2.49 mg/100 g FW | | |
| Gourds | Zucchini, raw | 1.32 mg/100 g FW | | |
| Leaf vegetables | Lettuce (green), raw | 0.04 mg/100 g FW | | |
| Shoot vegetables | Asparagus, raw | 23.20 mg/100 g FW | | |
| | Fruits and fruit products | | | |
| Berries | Black raspberry, raw | 19.00 mg/100 g FW | | |
| | Blackberry, raw | 3.89 mg/100 g FW | | |
| | Blackcurrant, raw | 4.65 mg/100 g FW | | |
| | Grape (green) | 0.12 mg/100 g FW | | |
| | Green currant | 6.06 mg/100 g FW | | |
| | Red raspberry, raw | 11.00 mg/100 g FW | | |
| | Redcurrant, raw | 0.44 mg/100 g FW | | |
| | White currant | 0.70 mg/100 g FW | | |
| Dried berries | Grape, raisin | 0.51 mg/100 g FW | | |
| Pomes | Apple (cider), whole | 0.25 mg/100 g FW | | |
| | Apple (dessert), peeled | 0.0000526 mg/100 g FW | | |
| | Apple (dessert), whole, raw | 0.22 mg/100 g FW | | |

| | Dane whole | 0.04 == -/400 = FNA | |
|-------------------------------------|---------------------------------|---------------------|--|
| | Pear, whole | 0.04 mg/100 g FW | |
| | Quince, peeled, raw | 0.51 mg/100 g FW | |
| Pome jams | Quince, jam | 0.05 mg/100 g FW | |
| | Quince, jelly | 0.00392 mg/100 g FW | |
| | Quince, peeled, jam | 0.19 mg/100 g FW | |
| Drupes | Apricot, raw | 0.83 mg/100 g FW | |
| | Nectarine, whole | 0.10 mg/100 g FW | |
| | Plum, fresh | 5.90 mg/100 g FW | |
| Dried drupes | Plum, prune | 2.50 mg/100 g FW | |
| Drupe jams | Apricot, jam | 1.42 mg/100 g FW | |
| | Seeds | | |
| Nuts | Almond | 0.25 mg/100 g FW | |
| | Pistachio, dehulled | 0.05 mg/100 g FW | |
| Pulses | Lentils, whole, raw | 0.52 mg/100 g FW | |
| | Seasonings | | |
| Herbs | Fenugreek, fresh | 1.86 mg/100 g FW | |
| | Marjoram, dried | 2.60 mg/100 g FW | |
| Spices | Capers | 332.29 mg/100 g FW | |
| | Non-alcoholic beverages | | |
| Fruit juices, berry juices | Sea-buckthorn berry, pure juice | 1.30 mg/100 mL | |
| Fruit juices, pome juices | Apple (cider), pure juice | 0.01 mg/100 mL | |
| | Apple (dessert), pure juice | 0.35 mg/100 mL | |
| Fruit juices, tropical fruit juices | Kiwi, juice from concentrate | 0.04 mg/100 mL | |
| | Kiwi, pure juice | 0.03 mg/100 mL | |
| Tea infusions | Tea (black), bottled | 19.68 mg/100 mL | |
| | Tea (black), infusion | 1.62 mg/100 mL | |
| | Tea (green), infusion | 1.46 mg/100 mL | |
| Alcoholic beverages | | | |
| Beers | Beer, regular | 0.09 mg/100 mL | |
| Wine, grapes | Wine, red | 0.81 mg/100 mL | |
| | Wine, white | 0.19 mg/100 mL | |
| Wine, berries | Blackcurrant, wine | 0.45 mg/100 mL | |
| | | | |

*Source: http://phenol-explorer.eu/

The oral bioavailability of dietary rutin was demonstrated in 12 healthy subjects after administration of tomato puree (25 g/day containing 2.7 mg/25 g of flavonoids), together with olive oil (5 g) for 14 days. The measured mean concentration of rutin in plasma was 0.10 μ mol/L,

with large inter-individual variation (0.08 - 0.30 μ mol/L), whereas the flavanol was not detected in 4 subjects [1]. However, in humans, rutin is not well absorbed in the small intestine, but is transported to the colon (about 80%) where metabolism takes place.

In 20 healthy subjects, about half of ingested rutin (440 mg/day for 7 days) was first deglycosylated to quercetin (the aglycone), and then metabolized to phenylacetic acids after cleavage of the quercetin ring by the colonic microflora. The latter were subsequently absorbed from the colon and further metabolized in the liver and kidneys. Indeed, the presence of homovanillic

acid (3-methoxy-4-hydroxyphenylacetic acid) in the urine is indicative of methylation, an important metabolic reaction that occurs in the liver (Table 4) [2]. Similarly, the very high levels of hippuric acid (N-benzoylglycine) measured in this study are consistent with the hepatic conjugation of benzoic acid with glycine to form hippuric acid [3].

Table 4. Urinary metabolites after rutin administration (440 mg/day for 7 days) in healthy subjects*

| Rutin metabolites | Concentration (µmol) in 24-h urine after 1 week |
|--------------------------------|---|
| 2,4-Dihydroxybenzoic acid | 16 |
| 2-Hydroxy-2-phenylacetic acid | 6 |
| 2-Hydroxyhippuric acid | 6.2 |
| 2-Hydroxyphenylacetic acid | 8.2 |
| 3,4-Dihydroxyphenylacetic acid | 52 |
| 3,5-Dihydroxybenzoic acid | 47 |
| 3-Hydroxyphenylacetic acid | 259 |
| 4-Hydroxybenzoic acid | 29 |
| 4-Hydroxyphenylacetic acid | 150 |
| Benzoic acid | 9 |
| Ferulic acid | 27 |
| Hippuric acid** | 2700 |
| Homovanillic acid | 103 |
| Phenylacetic acid | 22 |
| Protocatechuic acid | 13 |
| Sinapic acid | 26 |
| Syringic acid | 8.3 |
| Vanillic acid | 80 |

^{*}Source: http://phenol-explorer.eu/; [2]

Despite the plethora of *in vitro/in vivo* studies on the efficacy of rutin, for example as an anticancer and neuroprotective agent [4-6], more clinical trials are needed to substantiate the preclinical evidence. In fact,

over the past five years, we have found 614 articles in PubMed using 'rutin' [in title] as a search term, with only 4 clinical trials. Similarly, only 2 recruiting and not yet recruiting clinical trials were recorded in the US registry

^{**}In bold are the main hepatic metabolites of rutin

(https://www.clinicaltrials.gov/) (Table 5), whereas no clinical trials on rutin were registered in the EU registry.

Two out of four published articles were randomized controlled trials (RCTs) focusing on supplementation in patients with type 2 diabetes mellitus [7,8]. In one study, 500 mg of rutin daily for 3 months significantly reduced fasting blood glucose (FBG), insulin, glycosylated hemoglobin (HbA1c), low-density lipoprotein cholesterol (LDLc), triglycerides, very lowdensity lipoprotein, total cholesterol (TC), LDLc:HDLc (hig-density lipoprotein cholesterol) ratio, interleukin 6 and malondialdehyde, while HDL-c and total antioxidant capacity significantly increased in the rutin group compared to the placebo group [8]. Similarly, in the other study, rutin 60 mg in combination with vitamin C 160 mg administered three times a day in addition to the usual oral antidiabetic treatment for 8 weeks significantly reduced FBG, compared with the control (only antidiabetic treatment), but had no effect on HbA1c, FBG, TC, fasting insulin, and oxidative stress in diabetic patients [7].

In another study, a mixture of flavonoids including diosmin (150 mg), troxerutin (300 mg), rutin (250 mg), hesperidin (150 mg) and quercetin (150 mg) was used safely and effectively to manage bleeding from hemorrhoidal disease with minimal adverse events [9]. In the last clinical trial, monoglucosyl rutin (200 and 400 mg/day for 8 weeks), an enzymatically modified, watersoluble form of rutin, significantly reduced abdominal visceral fat in healthy subjects with a body mass index of ≥ 23 and ≤ 30 kg/m² [10].

Table 5. Clinical trials (recruiting and not yet recruiting) on rutin recorded on US registry*

| Title (identifier number) | Intervention/treatment | Condition | Primary outcome(s) |
|---------------------------------------|---------------------------------|---------------------|------------------------------|
| Evaluation of the effect of rutin and | Two tablets containing rutin 60 | End stage renal | Plasma levels of |
| vitamin C on the oxidative stress in | mg and ascorbic acid 160 mg | disease | malondialdehyde, C-reactive |
| hemodialysis patients (NCT04955145) | three times daily for 4 months | | protein, glutathione |
| | | | peroxidase, tumor necrosis |
| | | | factor-alpha and erythrocyte |
| | | | sedimentation rate |
| Evaluation of the effect of systemic | Tibrolin™ (trypsin 48 mg, | Post operative pain | Pain after surgery, facial |
| proteolytic enzyme therapy | bromelain 90 mg) and rutin 100 | | swelling and trismus 7 days |
| (NCT05681312) | mg for five days | | after surgery |

^{*}https://www.clinicaltrials.gov/

CONCLUSION:

Compelling evidence indicates that foods rich in flavonoids are healthy [11,12]. Rutin, in particular, can really be considered a promising bioactive component of many functional foods [13]. Based on clinical evidence, it may have beneficial effects on the improvement of metabolic parameters, in particular glycaemia, as well as

the inflammatory and oxidative status in diabetic patients. In addition to requiring further RCTs on rutin, a future trend is the use of this flavonoid in combination with conventional therapies, to potentiate the effectiveness of the latter. For instance, rutin *i*) can sensitize tumor cells resistant to anticancer drugs,

FFHD

reducing their side effects [4,14]; *ii*) reduce hyperglycemia (%HbA1c) in combination with the antidiabetic drugs acarbose and canagliflozin [15]; *iii*) improve diabetic neuropathy by potentiating the anti-inflammatory drug nimesulide [16]; and *iv*) manage osteoarthritis symptoms in combination with oral proteolytic enzymes [17].

Another relevant issue is the oral bioavailability of rutin which can be successfully improved with nanoformulations. The latter, in fact, can deliver bioactive compounds to specific target(s), facilitating their controlled release, as demonstrated for other phytochemicals including curcumin, also reducing the administered dose [18]. Rutin nanohybrids made of phenylboronic acid conjugated to nanomagnesia (MgO nanoparticles) exhibited a significant preclinical anticancer activity to chemoresistant breast cancer cells via oxidative burst (i.e., reactive oxygen species generation) and apoptotic cell death, whereas no notable systemic toxicity was documented in mice [19]. In

another *in vitro/in vivo* study, rutin nanoencapsulation in an innovative nanovesicle composed of saturated fatty acids and phytosterols increased oral bioavailability of the flavonoid in rats after a single administration. This nanoformulation has also been shown to be cytotoxic to hepatocellular carcinoma cells via cell cycle arrest [20]. Unfortunately, a reference anticancer drug was not used in either of these *in vivo* experiments. In any case, safety of nanoformulations must be ascertained, in terms of nanotoxicology, chronic exposure and interaction with drugs.

Competing interests: The authors declare that they have no competing interests.

Acknowledgment/Funding: Authors have not received funding for this article.

Author Contribution: All authors conceived and write the MS.

REFERENCES

- Simonetti, P., C. Gardana, P. Riso, P. Mauri, P. Pietta, and M. Porrini: Glycosylated flavonoids from tomato puree are bioavailable in humans. Nutrition Research 2005, 25(8):717-726.
 DOI: https://doi.org/10.1016/j.nutres.2005.05.001
- Olthof, M.R., P.C. Hollman, M.N. Buijsman, J.M. Van Amelsvoort, and M.B. Katan: Chlorogenic acid, quercetin-3-rutinoside and black tea phenols are extensively metabolized in humans. Journal of Nutrition 2003, 133(6):1806-1814. DOI: https://doi.org/10.1093/jn/133.6.1806
- Penczynski, K.J., D. Krupp, A. Bring, K. Bolzenius, T. Remer, and A.E. Buyken: Relative validation of 24-h urinary hippuric acid excretion as a biomarker for dietary flavonoid intake from fruit and vegetables in healthy adolescents. European Journal of Nutrition 2017, 56:757-766. DOI: https://doi.org/10.1007/s00394-015-1121-9
- Iriti, M., R. Kubina, A. Cochis, R. Sorrentino, E.M. Varoni, A. Kabała-Dzik, B. Azzimonti, A. Dziedzic, L. Rimondini, and R.D. Wojtyczka: Rutin, a quercetin glycoside, restores

- chemosensitivity in human breast cancer cells. Phytotherapy Research 2017, 31(10):1529-1538. DOI: https://doi.org/10.1002/ptr.5878
- Ramalingayya, G.V., S.P. Cheruku, P.G. Nayak, A. Kishore, R. Shenoy, C.M. Rao, and N. Krishnadas: Rutin protects against neuronal damage in vitro and ameliorates doxorubicin-induced memory deficits in vivo in Wistar rats. Drug Design, Development and Therapy 2017, 1011-1026. DOI: https://doi.org/10.2147/DDDT.S103511
- Asti, A.L., S. Crespi, T. Rampino, P. Zelini, M. Gregorini, A. Pascale,
 N. Marchesi, S. Saccucci, C. Colombani, S. Vitalini, and M. Iriti:
 Yet another in vitro evidence that natural compounds
 introduced by diet have anti-amyloidogenic activities and can
 counteract neurodegenerative disease depending on aging.
 Natural Product Research 2023, 1-6. DOI:
 https://doi.org/10.1080/14786419.2023.2192493
- 7. Ragheb, S.R., L.M. El Wakeel, M.S. Nasr, and N.A. Sabri: Impact of Rutin and Vitamin C combination on oxidative stress and

- glycemic control in patients with type 2 diabetes. Clinical Nutrition ESPEN 2020, 35:128-135. DOI: https://doi.org/10.1016/j.clnesp.2019.10.015
- Bazyar, H., L. Moradi, F. Zaman, and A. Zare Javid: The effects of rutin flavonoid supplement on glycemic status, lipid profile, atherogenic index of plasma, brain-derived neurotrophic factor (BDNF), some serum inflammatory, and oxidative stress factors in patients with type 2 diabetes mellitus: A double-blind, placebo-controlled trial. Phytotherapy Research 2023, 37(1):271-284. DOI: https://doi.org/10.1002/ptr.7611
- Corsale, I., P. Carrieri, J. Martellucci, A. Piccolomini, L. Verre, M. Rigutini, and S. Panicucci: Flavonoid mixture (diosmin, troxerutin, rutin, hesperidin, quercetin) in the treatment of I–III degree hemorroidal disease: a double-blind multicenter prospective comparative study. International Journal of Colorectal Disease 2018, 33:1595-1600. DOI: https://doi.org/10.1007/s00384-018-3102-y
- Martirosyan, D., and E. Miller. Bioactive compounds: The key to functional foods. Bioactive Compounds in Health and Disease 2018, 1(3):36-39. DOI: https://doi.org/10.31989/bchd.v1i3.539
- 11. Devkota, H.P., A. Kurizaki, K. Tsushiro, A. Adhikari-Devkota, K. Hori, M. Wada, and T. Watanabe: Flavonoids from the leaves and twigs of *Lindera sericea* (Seibold et Zucc.) Blume var. *sericea* (Lauraceae) from Japan and their bioactivities. Functional Foods in Health and Disease 2021, 11(1):34-43. DOI: https://www.doi.org/10.31989/ffhd.v11i1.769
- Madardam, J., S. Wattanachant, and C.T. Yupanqui: Evaluation of the antioxidant activity and nitric oxide production effect of formulated crispy vegetables from thermal processing of *Amaranthus viridis* and *Sauropus androgynous*. Functional Foods in Health and Disease 2023, 13(9):409-423. DOI: https://www.doi.org/10.31989/ffhd.v13i9.1116
- Hashizume, Y., and M. Tandia: The reduction impact of monoglucosyl rutin on abdominal visceral fat: A randomized, placebo-controlled, double-blind, parallel-group. Journal of Food Science 2020, 85(10):3577-3589. DOI: https://doi.org/10.1111/1750-3841.15429

14. Satari, A., S. Ghasemi, S. Habtemariam, S. Asgharian, and Z. Lorigooini: Rutin: a flavonoid as an effective sensitizer for anticancer therapy; insights into multifaceted mechanisms and applicability for combination therapy. Evidence-based Complementary and Alternative Medicine 2021, Article ID:9913179. DOI: https://doi.org/10.1155/2021/9913179

FFHD

- 15. Valdes, M., F. Calzada, J. Martínez-Solís, and J. Martínez-Rodríguez: Antihyperglycemic Effects of Annona cherimola Miller and the Flavonoid Rutin in Combination with Oral Antidiabetic Drugs on Streptozocin-Induced Diabetic Mice. Pharmaceuticals 2023, 16(1):112. DOI: https://doi.org/10.3390/ph16010112
- Mittal, R., A. Kumar, D.P. Singh, M. Bishnoi, and T.C. Nag: Ameliorative potential of rutin in combination with nimesulide in STZ model of diabetic neuropathy: targeting Nrf2/HO-1/NF-kB and COX signalling pathway. Inflammopharmacology 2018, 26:755-768. DOI: https://doi.org/10.1007/s10787-017-0413-5
- Henrotin, Y.E., C. Michlmayr, S.M. Rau, A.M. Quirke, M. Bigoni, and M.A. Ueberall: Combination of enzymes and rutin to manage osteoarthritis symptoms: Lessons from a narrative review of the literature. Rheumatology and Therapy 2022, 9(5):1305-1327. DOI: https://doi.org/10.6084/m9.figshare.20058908
- Salehi, B., Rodrigues, C.F., Peron G., Dall'Acqua S, Sharifi-Rad J., Azmi L., Shukla I, Singh Baghel U, Curcumin nanoformulations for antimicrobial and wound healing purposes. Phytotherapy Research 2021,35(5):2487-2499. DOI: 10.1002/ptr.6976.
- Singh, T.A., P. Sadhukhan, N. Ghosh, N. Thakur, A. Sharma, N. Tejwan, A. Pabbathi, J. Das, and P.C. Sil. Targeted delivery of rutin into breast cancer cells via using phenylboronic acid functionalized MgO nanoparticles. Materials Science and Engineering B 2023, 296:116623. DOI: https://doi.org/10.1016/j.mseb.2023.116623.
- AbouSamra, M. M., S.M. Afifi, A.F. Galal, and R. Kamel. Rutin-loaded Phyto-Sterosomes as a potential approach for the treatment of hepatocellular carcinoma: In-vitro and in-vivo studies. Journal of Drug Delivery Science and Technology 2023, 79:104015. DOI: https://doi.org/10.1016/j.jddst.2022.104015.